Cargando…

TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies

INTRODUCTION: Recently an association between a genetic variation in TRAF1/C5 and mortality from sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of death, cardiovascular disease, may have been missed in that study, since patients were enrolled at an advanced disease...

Descripción completa

Detalles Bibliográficos
Autores principales: van Nies, Jessica AB, Marques, Rute B, Trompet, Stella, de Jong, Zuzana, Kurreeman, Fina AS, Toes, Rene EM, Jukema, J Wouter, Huizinga, Tom WJ, van der Helm-van Mil, Annette HM
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888185/
https://www.ncbi.nlm.nih.gov/pubmed/20205706
http://dx.doi.org/10.1186/ar2947
_version_ 1782182631826259968
author van Nies, Jessica AB
Marques, Rute B
Trompet, Stella
de Jong, Zuzana
Kurreeman, Fina AS
Toes, Rene EM
Jukema, J Wouter
Huizinga, Tom WJ
van der Helm-van Mil, Annette HM
author_facet van Nies, Jessica AB
Marques, Rute B
Trompet, Stella
de Jong, Zuzana
Kurreeman, Fina AS
Toes, Rene EM
Jukema, J Wouter
Huizinga, Tom WJ
van der Helm-van Mil, Annette HM
author_sort van Nies, Jessica AB
collection PubMed
description INTRODUCTION: Recently an association between a genetic variation in TRAF1/C5 and mortality from sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of death, cardiovascular disease, may have been missed in that study, since patients were enrolled at an advanced disease stage. Therefore, we used an inception cohort of RA patients to investigate the association between TRAF1/C5 and cardiovascular mortality, and replicate the findings on all-cause mortality. As TRAF1/C5 associated mortality may not be restricted to RA, we also studied a large cohort of non-RA patients. METHODS: 615 RA patients from the Leiden Early Arthritis Clinic (EAC) (mean follow-up 7.6 years) were genotyped for rs10818488. In addition 5634 persons enrolled in the PROspective Study of Pravastatin in the Elderly at Risk (mean follow-up 3.2 years) were genotyped for rs2416808 (R(2 )>0.99 with rs10818488). The life/death status was determined and for the deceased persons the cause of death was ascertained. Cox proportional hazards and regression models were used to assess hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Seventy-seven RA patients died. The main death causes in RA patients were cardiovascular diseases (37.7%), cancer (28.6%) and death due to infections (9.1%). No association was observed between the rs10818488 susceptible genotype AA and cardiovascular mortality (HR 1.08 95%CI 0.54 to 2.15) and all-cause mortality (HR 0.81 95%CI 0.27 to 2.43). Similar findings were observed for rs2416808 susceptible genotype GG in the non-RA cohort (HR 0.99; 95%CI 0.79 to 1.25 and HR 0.89; 95%CI 0.64 to 1.25, respectively). CONCLUSIONS: The TRAF1/C5 region is not associated with an increased mortality risk.
format Text
id pubmed-2888185
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28881852010-06-21 TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies van Nies, Jessica AB Marques, Rute B Trompet, Stella de Jong, Zuzana Kurreeman, Fina AS Toes, Rene EM Jukema, J Wouter Huizinga, Tom WJ van der Helm-van Mil, Annette HM Arthritis Res Ther Research article INTRODUCTION: Recently an association between a genetic variation in TRAF1/C5 and mortality from sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of death, cardiovascular disease, may have been missed in that study, since patients were enrolled at an advanced disease stage. Therefore, we used an inception cohort of RA patients to investigate the association between TRAF1/C5 and cardiovascular mortality, and replicate the findings on all-cause mortality. As TRAF1/C5 associated mortality may not be restricted to RA, we also studied a large cohort of non-RA patients. METHODS: 615 RA patients from the Leiden Early Arthritis Clinic (EAC) (mean follow-up 7.6 years) were genotyped for rs10818488. In addition 5634 persons enrolled in the PROspective Study of Pravastatin in the Elderly at Risk (mean follow-up 3.2 years) were genotyped for rs2416808 (R(2 )>0.99 with rs10818488). The life/death status was determined and for the deceased persons the cause of death was ascertained. Cox proportional hazards and regression models were used to assess hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Seventy-seven RA patients died. The main death causes in RA patients were cardiovascular diseases (37.7%), cancer (28.6%) and death due to infections (9.1%). No association was observed between the rs10818488 susceptible genotype AA and cardiovascular mortality (HR 1.08 95%CI 0.54 to 2.15) and all-cause mortality (HR 0.81 95%CI 0.27 to 2.43). Similar findings were observed for rs2416808 susceptible genotype GG in the non-RA cohort (HR 0.99; 95%CI 0.79 to 1.25 and HR 0.89; 95%CI 0.64 to 1.25, respectively). CONCLUSIONS: The TRAF1/C5 region is not associated with an increased mortality risk. BioMed Central 2010 2010-03-05 /pmc/articles/PMC2888185/ /pubmed/20205706 http://dx.doi.org/10.1186/ar2947 Text en Copyright ©2010 van Nies et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
van Nies, Jessica AB
Marques, Rute B
Trompet, Stella
de Jong, Zuzana
Kurreeman, Fina AS
Toes, Rene EM
Jukema, J Wouter
Huizinga, Tom WJ
van der Helm-van Mil, Annette HM
TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
title TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
title_full TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
title_fullStr TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
title_full_unstemmed TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
title_short TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
title_sort traf1/c5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888185/
https://www.ncbi.nlm.nih.gov/pubmed/20205706
http://dx.doi.org/10.1186/ar2947
work_keys_str_mv AT vanniesjessicaab traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT marquesruteb traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT trompetstella traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT dejongzuzana traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT kurreemanfinaas traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT toesreneem traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT jukemajwouter traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT huizingatomwj traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies
AT vanderhelmvanmilannettehm traf1c5polymorphismisnotassociatedwithincreasedmortalityinrheumatoidarthritistwolargelongitudinalstudies